PORTFOLIO
Meet the AIF portfolio companies that are transforming the status quo for ASD, neurodevelopmental disorders, mental health issues, and other complex chronic conditions.
We invest in companies that will move the needle in how we diagnose, treat, and provide lifelong support to individuals with ASD, neurodevelopmental disorders, mental health issues, and other complex chronic conditions.
Life Sciences
DATA & TECH-ENABLED SERVICES
MEET THE COMPANIES
Auticon is an information technology and communications technology (ICT) firm that is the global leader in employing neurodiverse adults as data technology solution providers. Auticon harnesses a uniquely qualified team of neurodiverse employees via a proprietary model that implements AI-driven analytics, process automation and complex software development solutions for clients. Originally founded in Germany in 2011, Auticon has since expanded its operations to employ ~250 autistic consultants across the United States, United Kingdom, France, Switzerland, Canada, Italy, and Australia. Auticon partners with large, multi-national clients, including Merck, Airbus, Deloitte, KPMG, Johnson & Johnson, Salesforce, Disney, Siemens, BMW, Volkswagen, Porsche, Virgin, and the UN.
BioROSA is developing a blood test that will detect ASD in children. A positive BioROSA test can allow for early intervention services to begin, which have been shown to improve language, social skills, and IQ for many children with ASD.
Bluebird Kids Health is a value-based pediatric platform improving access to care for the 40 million children covered by Medicaid and CHIP. With Medicaid reimbursement rates significantly lower than commercial rates, most pediatricians cap Medicaid patients at 10–15%, leaving many low-income communities without adequate care. This shortage forces families to rely on emergency rooms (ER) for routine visits, driving up costs and straining the healthcare system. Bluebird is solving this problem by launching de novo clinics in underserved areas and partnering with Medicaid Managed Care Organizations to implement value-based care contracts that align financial incentives with better outcomes. This model reduces avoidable ER visits and improves care coordination, especially supporting children with complex care needs.
Camber is on a mission to make behavioral health more available and accessible by building software for behavioral health clinicians to improve quality of care. With applications for Applied Behavior Analysis (ABA), Speech-Language Pathology (SLP), and Occupational Therapy (OT) providers, Camber’s SaaS platform alleviates pain points that have become status quo in behavioral health revenue cycle management, including lack of transparent reporting, unstructured billing labels, manual processes, and inconsistent customer support. These problems result in slow insurance reimbursement and more time spent on practice administration. Camber’s solution enhances data visibility with claims and task dashboards, prevents denials through a billing engine trained on millions of claims, and integrates directly with EHR systems—all within a user-friendly platform requiring minimal training. The Camber model streamlines and replaces manual efforts so clinicians can focus on what they do best: providing high-quality care.
Cortica is the market leader in bringing together all the resources a child and family need (pediatric neurology, genetics, and other medical expertise, behavioral therapists, speech therapists, and more), addressing underlying both behavioral and medical conditions using custom built technology for care coordination and data capture. The Company’s robust array of screening tools, services, and interventions enables Cortica to deliver programs that are tailored to the unique medical and behavioral needs of the individual. While over half of the Company’s patients are autistic, Cortica’s model allows flexibility to address any condition that impacts brain function or development (i.e., epilepsy, ADHD, brain injury, mental health conditions, learning disabilities, etc.), many of which co-occur with autism. Cortica’s coordinated approach leads to best-in-class member satisfaction and empowers families to achieve long-lasting, transformative results.
Eleplan is a caregiving platform that simplifies care coordination through AI-powered, customizable plans. Designed for families managing complex health needs, Eleplan centralizes essential information such as medical records, daily routines, and contact details into a secure digital hub. Its features include personalized care plans, a searchable knowledge base, and secure document sharing, all accessible via web and mobile applications. With a focus on reducing caregiver stress and enhancing collaboration among care teams, Eleplan offers a streamlined solution for managing caregiving responsibilities.
Floreo is leveraging the power of virtual reality to provide a method of teaching social, behavioral, communication, and life skills for individuals with ASD, ADHD, anxiety, and related diagnoses. With a mobile-friendly platform that is remotely accessible at an affordable price point, Floreo is addressing several key barriers to care.
Jaguar Gene Therapy is a clinical-stage biotechnology company focused on accelerating treatments for ASD, Phelan-McDermid Syndrome, Galactosemia, and Type 1 diabetes. An estimated 1% of diagnosed ASD cases, approximately 484,000 patients globally and 46,000 in the United States, are linked to mutations or deletions in the SHANK3 gene. These genetic changes can result in cognitive and motor impairments. Currently, no approved treatments exist for these conditions. Jaguar’s lead candidate targets ASD caused by SHANK3 haploinsufficiency and Phelan-McDermid Syndrome. To advance its programs, Jaguar works with Advanced Medicine Partners, a process/analytics development and manufacturing company with proprietary technology for producing top quality, high-yield viral vectors.
Joshin is using a tech-enabled platform to match special needs caregivers with the 1-in-5 families requiring specialized care. For a monthly fee, families obtain access to a local network of pre-screened and qualified caregivers, enabling them to build and coordinate scheduling for a “care team” of individuals equipped to handle the specialized needs of their child.
MARAbio is a first-of-its-kind actionable diagnostic test for assessing the risk of having an autistic child in an estimated $4B market. MARAbio has exclusively licensed a unique technology from the UC Davis MIND Institute. The technology identifies the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism representing an estimated 20% of overall cases, through a new risk assessment test for prospective mothers before (not during) pregnancy and for mothers during the early postnatal period.
SpectrumAi develops innovative solutions for life-changing therapies, starting with applied behavioral analysis. Twyll is an electronic health record purpose-built to modernize ABA and reduce supervisor and technician burnout while paving a path to value-based care. Patterns network analytics lets payors collaborate with network providers to better manage access and utilization to meet their members’ needs.
Suggestic is an AI transformation partner for health and wellness organizations, delivering custom AI solutions and personalized engagement at scale through its comprehensive Health Engagement Ecosystem. By combining deep healthcare expertise with enterprise-validated technology, Suggestic helps clients implement solutions that bridge the gap between technology potential and real-world implementation. The platform integrates AI-powered virtual coaching, telehealth capabilities, and advanced analytics to create measurable outcomes for clients. With 100+ successful implementations for organizations ranging from digital health companies to global enterprises, Suggestic’s proven rapid-deployment methodology enables healthcare organizations to achieve meaningful results in weeks rather than months.
Unison Therapy Services is a leading provider of multidisciplinary therapeutic services for children, offering both school- and community-based care. The shortage of qualified special education professionals places significant pressure on school districts, often leaving them vulnerable to compliance risks and financial liabilities. As a result, many schools turn to outsourcing as a cost-effective solution to remain compliant while reducing the financial burden of in-house staffing shortages. Unison’s network of clinicians offers speech, behavioral, psychological, and physical and occupational therapy for children with developmental delays, ASD, and behavioral challenges.
Vertero Therapeutics is pioneering science beyond the brain to treat neurodegenerative diseases at their source. Vertero’s development pipeline of differentiated therapies targets the peripheral nervous system to delay onset and slow progression of challenging conditions such as Parkinson’s disease. The company’s lead program, VT-5006, is designed to precisely treat a validated target in the gut that feeds the protein aggregation and inflammation implicated in Parkinson’s disease. Vertero is preparing to initiate a Phase 1 clinical trial of VT-5006. The company also has an asset targeting bile acid dysregulation in early development for undisclosed indications.
Yamo Pharmaceuticals is a drug discovery company developing a Phase II compound for the treatment of core ASD symptoms. With no safe, effective therapeutics currently on the market for autism, Yamo’s drug candidate (L1-79) offers an alternative to the two currently approved drugs for treating irritability in ASD, which are both antipsychotics with black box warnings. Preliminary trial results showed L1-79 to be well-tolerated while decreasing autism severity and improving socialization and communication skills. L1-79 received the FDA Fast Track Designation in 2018 and was sought by parents for a Compassionate Use Waiver.